Shelley J. Force Aldred, Ph.D.
Affiliations: | Stanford University, Palo Alto, CA |
Google:
"Shelley Force Aldred"Mean distance: 16440.9
Parents
Sign in to add mentor| Richard Morris Myers | grad student | 2005 | Stanford | |
| (Large scale identification and analysis of human transcriptional regulatory elements.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Trinklein ND, Pham D, Schellenberger U, et al. (2019) Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies. Mabs |
| Clarke S, Dang K, Li Y, et al. (2019) A novel CD3xPSMA bispecific antibody for efficient T cell mediated killing of prostate tumor cells with minimal cytokine release. Journal of Clinical Oncology. 37: 324-324 |
| Buelow B, Clarke S, Dang K, et al. (2019) Evaluation of monovalent versus biparatopic CD3xPSMA bispecific antibodies for t-cell mediated killing of prostate tumor cells with minimal cytokine release. Journal of Clinical Oncology. 37: e16519-e16519 |
| Malik H, Buelow B, Rangaswamy U, et al. (2019) TNB-486, a Novel Fully Human Bispecific CD19 x CD3 Antibody That Kills CD19-Positive Tumor Cells with Minimal Cytokine Secretion Blood. 134: 4070-4070 |
| Clarke SC, Ma B, Trinklein ND, et al. (2018) Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies. Frontiers in Immunology. 9: 3037 |
| Buelow B, Choudhry P, Clarke S, et al. (2018) Development of a fully human t-cell engaging bispecific antibody for the treatment of multiple myeloma. Journal of Clinical Oncology. 36: 60-60 |
| Force Aldred S, Boudreau A, Buelow B, et al. (2018) Multispecific antibodies targeting CD38 show potent tumor-specific cytotoxicity. Journal of Clinical Oncology. 36: 57-57 |
| Rangaswamy U, Boudreau A, Buelow B, et al. (2018) A novel T-cell bispecific antibody platform for efficient T-cell mediated killing of tumor cells with minimal cytokine release. Journal of Clinical Oncology. 36: 209-209 |
| Buelow B, Choudry P, Clarke S, et al. (2018) Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma. Journal of Clinical Oncology. 36: 8034-8034 |
| Malik H, Buelow B, Avanzino B, et al. (2018) A Novel Fully Human Bispecific CD19 x CD3 Antibody That Kills Lymphoma Cells with Minimal Cytokine Secretion Blood. 132: 1671-1671 |